Pernix Therapeutics (PTX) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pernix Therapeutics Reports Third Quarter 2015 Financial Results
November 5, 2015 6:50 AM ESTRevenue Increases 54% Year-Over-Year
Company Reiterates Financial Guidance
MORRISTOWN, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015. Third Quarter and Recent Business Highlights:
Increased Treximet total prescriptions by 7% and new prescriptions by 13% versus the second quarter of 2015;Increased Silenor total prescriptions by 7%, and new prescriptions by 2% compared to the second quarter of... More